中国药业2017，Vol.26Issue(6)：49-51,3.DOI:10.3969/j.issn.1006-4931.2017.06.015
非瓣膜性房颤达比加群酯抗凝治疗的疗效及安全性评价
Clinical Observation of Dabigatran and Warfarin in Treating Nonvalvular Atrial Fibrillation
卢奕 1温连安 1李东 2夏志琦 1朱蕾1
作者信息
- 1. 深圳市孙逸仙心血管医院,广东 深圳 518020
- 2. 暨南大学第二临床医学院·深圳市人民医院临床药学研究室,广东 深圳 518020
- 折叠
摘要
Abstract
Objective To discuss the clinical effects and safety of Dabigatran and Warfarin in treating patients with nonvalvular atrial fibrillation ( NVAF ) . Methods 64 patients with NVAF were selected and randomly divided into the Dabigatran group and the Warfarin group,32 cases in each group. The coagulation parameters of the two groups before treatment and 2 months after treatment were com-pared,as well as the occurrence of embolism and bleeding related events. Results The levels of PT,APTT,TT,FIB,INR had been in-creased in the two group after 2-month treatment(p < 0. 05). The incidence rate of slight bleeding was 6. 25% in the Dabigatran group,which was obviously lower than 15. 62% that in the Warfarin group(p < 0. 05). Conclusion The efficacy of Dabigatran in the prevention of embolization and ischemic strohe in NVAF patients is similar to that of Warfarin,but dabigatran is more safe and worthy of clinical promotion.关键词
达比加群酯/华法林/非瓣膜性房颤/疗效/安全性Key words
dabigatran/warfarin/nonvalvular atrial fibrillation/efficacy/safety分类
医药卫生引用本文复制引用
卢奕,温连安,李东,夏志琦,朱蕾..非瓣膜性房颤达比加群酯抗凝治疗的疗效及安全性评价[J].中国药业,2017,26(6):49-51,3.
